Vanguard Group’s NeuroMetrix, Inc. Common Stock NURO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,124
| Closed | -$67.2K | – | 4377 |
|
|
2025
Q1 | $67.2K | Hold |
15,124
| – | – | ﹤0.01% | 4172 |
|
|
2024
Q4 | $60K | Hold |
15,124
| – | – | ﹤0.01% | 4201 |
|
|
2024
Q3 | $61.9K | Hold |
15,124
| – | – | ﹤0.01% | 4233 |
|
|
2024
Q2 | $55.8K | Hold |
15,124
| – | – | ﹤0.01% | 4279 |
|
|
2024
Q1 | $64.3K | Hold |
15,124
| – | – | ﹤0.01% | 4286 |
|
|
2023
Q4 | $54.4K | Buy |
15,124
+1,143
| +8% | +$4.8K | ﹤0.01% | 4361 |
|
|
2023
Q3 | $80.1K | Sell |
13,981
-17,475
| -56% | -$113K | ﹤0.01% | 4368 |
|
|
2023
Q2 | $245K | Sell |
31,456
-12,311
| -28% | -$114K | ﹤0.01% | 4276 |
|
|
2023
Q1 | $515K | Hold |
43,767
| – | – | ﹤0.01% | 4119 |
|
|
2022
Q4 | $522K | Buy |
43,767
+13
| +0% | +$185 | ﹤0.01% | 4086 |
|
|
2022
Q3 | $977K | Buy |
43,754
+4,362
| +11% | +$120K | ﹤0.01% | 4008 |
|
|
2022
Q2 | $1.16M | Hold |
39,392
| – | – | ﹤0.01% | 4035 |
|
|
2022
Q1 | $1.31M | Buy |
39,392
+2,458
| +7% | +$87.4K | ﹤0.01% | 4122 |
|
|
2021
Q4 | $1.48M | Sell |
36,934
-10,126
| -22% | -$599K | ﹤0.01% | 4144 |
|
|
2021
Q3 | $3.82M | Buy |
47,060
+38,781
| +468% | +$3.47M | ﹤0.01% | 3810 |
|
|
2021
Q2 | $226K | Hold |
8,279
| – | – | ﹤0.01% | 4356 |
|
|
2021
Q1 | $226K | Buy |
8,279
+6,286
| +315% | +$191K | ﹤0.01% | 4240 |
|
|
2020
Q4 | $50K | Hold |
1,993
| – | – | ﹤0.01% | 4180 |
|
|
2020
Q3 | $27K | Hold |
1,993
| – | – | ﹤0.01% | 4091 |
|
|
2020
Q2 | $33K | Buy |
+1,993
| New | +$34.4K | ﹤0.01% | 4044 |
|
|
2019
Q4 | – | Sell |
-149
| Closed | -$4K | – | 4150 |
|
|
2019
Q3 | $4K | Hold |
149
| – | – | ﹤0.01% | 4152 |
|
|
2019
Q2 | $5K | Hold |
149
| – | – | ﹤0.01% | 4167 |
|
|
2019
Q1 | $13K | Hold |
149
| – | – | ﹤0.01% | 4108 |
|
|
2018
Q4 | $9K | Hold |
149
| – | – | ﹤0.01% | 4144 |
|
|
2018
Q3 | $16K | Buy |
+149
| New | +$15.1K | ﹤0.01% | 4158 |
|
|
2017
Q2 | – | Sell |
-50
| Closed | -$20K | – | 4085 |
|
|
2017
Q1 | $20K | Buy |
50
+5
| +11% | +$2.16K | ﹤0.01% | 4057 |
|
|
2016
Q4 | $21K | Hold |
45
| – | – | ﹤0.01% | 4068 |
|
|
2016
Q3 | $44K | Hold |
45
| – | – | ﹤0.01% | 4041 |
|
|
2016
Q2 | $48K | Buy |
45
+14
| +45% | +$15.9K | ﹤0.01% | 4080 |
|
|
2016
Q1 | $36K | Buy |
31
+11
| +55% | +$11.4K | ﹤0.01% | 4099 |
|
|
2015
Q4 | $25K | Buy |
20
+7
| +54% | +$12.4K | ﹤0.01% | 4166 |
|
|
2015
Q3 | $29K | Hold |
13
| – | – | ﹤0.01% | 4163 |
|
|
2015
Q2 | $30K | Buy |
13
+6
| +86% | +$18K | ﹤0.01% | 4174 |
|
|
2015
Q1 | $30K | Hold |
7
| – | – | ﹤0.01% | 4137 |
|
|
2014
Q4 | $35K | Hold |
7
| – | – | ﹤0.01% | 4028 |
|
|
2014
Q3 | $32K | Buy |
7
+2
| +40% | +$9.33K | ﹤0.01% | 4001 |
|
|
2014
Q2 | $27K | Hold |
5
| – | – | ﹤0.01% | 3959 |
|
|
2014
Q1 | $33K | Buy |
+5
| New | +$32.2K | ﹤0.01% | 3928 |
|
Vanguard Group's NURO Position: Q2 2025 in Review
Vanguard Group sold out of NeuroMetrix, Inc. Common Stock (NURO) in Q2 2025, closing a stake of 15,124 shares — an estimated $67.2K sold.
Vanguard Group first reported a position in NURO in Q1 2014 and held it in 38 quarters. The position peaked at $3.82M in Q3 2021. 0 funds tracked by Wall St. Rank hold NURO as of Q2 2025.
- Vanguard Group reported no remaining NeuroMetrix, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Vanguard Group sold 15,124 NeuroMetrix, Inc. Common Stock shares in Q2 2025, an estimated $67.2K.
- Vanguard Group first reported a position in NeuroMetrix, Inc. Common Stock in Q1 2014 and held it in 38 quarters.
- Vanguard Group's NeuroMetrix, Inc. Common Stock position peaked at $3.82M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NeuroMetrix, Inc. Common Stock as of Q2 2025.
Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.